Gastrin Receptor Pharmacology

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2012 Sep 18

PMID 22983899

Citations 14

Authors

Graham J Dockray

Andy Moore

Andrea Varro

D Mark Pritchard

Affiliations

Soon will be listed here.

Abstract

C-terminally amidated gastrins act at cholecystokinin-2 receptors (CCK2R), which are normally expressed by gastric parietal and enterochromaffin-like (ECL) cells and smooth muscle; there is also extensive expression in the CNS where the main endogenous ligand is cholecystokinin. A variety of neoplasms express CCK2R, or splice variants, including neuroendocrine, pancreatic, medullary thyroid and lung cancers. Other products of the gastrin gene (progastrin, the Gly-gastrins) may stimulate cell proliferation but are not CCK2R ligands. Depending on the cell type, stimulation of CCK2R evokes secretion, increases proliferation and cell migration, inhibits apoptosis, and controls the expression of various genes. These effects are mediated by increased intracellular calcium and activation of protein kinase C, MAPkinase and other protein kinase cascades. There has been recent progress in developing CCK2R ligands that can be used for imaging tumours expressing the receptor. New antagonists have also been developed, and there is scope for using these for suppression of gastric acid and for treatment of neuroendocrine and other CCK2R-expressing tumours.

Citing Articles

Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.

Puscasu C, Negres S, Zbarcea C, Chirita C Life (Basel). 2024; 14(11).

PMID: 39598298 PMC: 11595627. DOI: 10.3390/life14111500.

Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice.

Bernard A, Mroue M, Bourthoumieu S, Boyce M, Richard L, Sturtz F Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399359 PMC: 10892341. DOI: 10.3390/ph17020144.

Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology.

Chen D, Hagen S, Boyce M, Zhao C J Neuroendocrinol. 2023; 35(11):e13305.

PMID: 37317882 PMC: 10656367. DOI: 10.1111/jne.13305.

The immune microenvironment in gastric adenocarcinoma.

Zavros Y, Merchant J Nat Rev Gastroenterol Hepatol. 2022; 19(7):451-467.

PMID: 35288702 PMC: 9809534. DOI: 10.1038/s41575-022-00591-0.

Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer.

Smith J, Cao H, Chen W, Mahmood K, Phillips T, Sutton L Front Oncol. 2021; 11:788875.

PMID: 34926305 PMC: 8672297. DOI: 10.3389/fonc.2021.788875.

References

Fjeldbo C, Bakke I, Erlandsen S, Holmseth J, Laegreid A, Sandvik A . Gastrin upregulates the prosurvival factor secretory clusterin in adenocarcinoma cells and in oxyntic mucosa of hypergastrinemic rats. Am J Physiol Gastrointest Liver Physiol. 2011; 302(1):G21-33. DOI: 10.1152/ajpgi.00197.2011. View

Kan Z, Jaiswal B, Stinson J, Janakiraman V, Bhatt D, Stern H . Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010; 466(7308):869-73. DOI: 10.1038/nature09208. View

Roosenburg S, Laverman P, van Delft F, Boerman O . Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids. 2010; 41(5):1049-58. PMC: 3205271. DOI: 10.1007/s00726-010-0501-y. View

Ferrand A, Lachal S, Bramante G, Kovac S, Shulkes A, Baldwin G . Stimulation of proliferation in the colorectal mucosa by gastrin precursors is blocked by desferrioxamine. Am J Physiol Gastrointest Liver Physiol. 2010; 299(1):G220-7. PMC: 2904120. DOI: 10.1152/ajpgi.00046.2010. View

Song Y, Yue Z, Wang Z, Xu Y, Luo Y, Xu H . MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer. 2011; 10:1. PMC: 3024301. DOI: 10.1186/1476-4598-10-1. View

Fourmy D, Gigoux V, Reubi J . Gastrin in gastrointestinal diseases. Gastroenterology. 2011; 141(3):814-818.e1-3. DOI: 10.1053/j.gastro.2011.07.006. View

Aloj L, Aurilio M, Rinaldi V, dAmbrosio L, Tesauro D, Peitl P . Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging. 2011; 38(8):1417-25. DOI: 10.1007/s00259-011-1816-y. View

Soll A . The interaction of histamine with gastrin and carbamylcholine on oxygen uptake by isolated mammalian parietal cells. J Clin Invest. 1978; 61(2):381-9. PMC: 372548. DOI: 10.1172/JCI108948. View

Burkitt M, Varro A, Pritchard D . Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2008; 15(1):1-16. PMC: 2653300. DOI: 10.3748/wjg.15.1. View

10.

Berna M, Tapia J, Sancho V, Jensen R . Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol. 2007; 7(6):583-92. PMC: 2186776. DOI: 10.1016/j.coph.2007.09.011. View

11.

Patel O, Marshall K, Bramante G, Baldwin G, Shulkes A . The C-terminal flanking peptide (CTFP) of progastrin inhibits apoptosis via a PI3-kinase-dependent pathway. Regul Pept. 2010; 165(2-3):224-31. DOI: 10.1016/j.regpep.2010.08.005. View

12.

Berna M, Seiz O, Nast J, Benten D, Blaker M, Koch J . CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production. J Biol Chem. 2010; 285(50):38905-14. PMC: 2998120. DOI: 10.1074/jbc.M110.125534. View

13.

Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S . Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther. 2012; 36(2):181-9. DOI: 10.1111/j.1365-2036.2012.05143.x. View

14.

Laverman P, Joosten L, Eek A, Roosenburg S, Peitl P, Maina T . Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging. 2011; 38(8):1410-6. PMC: 3127012. DOI: 10.1007/s00259-011-1806-0. View

15.

Morton M, Prendergast C, Barrett T . Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer. Trends Pharmacol Sci. 2011; 32(4):201-5. DOI: 10.1016/j.tips.2011.02.003. View

16.

Song Y, Xu Y, Wang Z, Chen Y, Yue Z, Gao P . MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int J Cancer. 2011; 131(5):1042-51. DOI: 10.1002/ijc.26485. View

17.

Tieppo C, Betterle C, Basso D, Mescoli C, Rugge M, Martini C . Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination. Cancer Immunol Immunother. 2011; 60(7):1057-60. PMC: 11028879. DOI: 10.1007/s00262-011-1031-5. View

18.

von Guggenberg E, Rangger C, Sosabowski J, Laverman P, Reubi J, Virgolini I . Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies. Mol Imaging Biol. 2011; 14(3):366-75. DOI: 10.1007/s11307-011-0506-2. View

19.

Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El-Serag H . Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther. 2011; 33(7):829-36. DOI: 10.1111/j.1365-2036.2011.04592.x. View

20.

Kumari S, Chowdhury J, Mishra A, Chandna S, Saluja D, Chopra M . Synthesis and evaluation of a fluorescent non-peptidic cholecystokinin-B/gastrin receptor specific antagonist for cancer cell imaging. Chembiochem. 2011; 13(2):282-92. DOI: 10.1002/cbic.201100593. View